PPAR-γ agonist attenuates inflammation in aortic aneurysm patients
Tóm tắt
Peroxisome proliferator-activated receptor (PPAR) -γ agonist, which is an anti-diabetes drug and reduces expression of tumor necrosis factor (TNF)-α, reported to have the effects for anti-inflammation in our body. In cardiovascular fields, this PPAR-γ agonist already reported to suppress progression of coronary atherosclerosis. Various cytokines, which is secreted from fat tissues around artery, promote atherosclerosis and/or aneurysmal changes in aorta/artery. Objective of our study is to clarify whether PPAR-γ agonist has anti-inflammatory effects in aorta of patients with aortic aneurysm (AA). The medical ethics committee in Tokushima University Hospital approved protocol for this study. Sixteen patients with AA (more than 5 cm in diameter, scheduled open surgery) were divided into two groups; one is PPAR-γ agonist administrating group
$$\langle$$
n = 6, group P
$$\rangle$$
, and another is the without group
$$\langle$$
n = 10, group C
$$\rangle$$
. PPAR-γ agonist, whose dose was 15 mg/day, was administrated in the group P for more than 2 months before aneurysectomy and grafting (mean; 4.2 ± 3.4 months) (Supplemental Table 1). Biopsy specimens were obtained from abdominal subcutaneous fat, greater omentum, retroperitoneal periaortic fat and aneurysmal wall in surgical procedure. Blood examination also achieved before/after procedure. Harvested specimens were analyzed with histology (HE and EVG), immunohistochemistry (macrophage) and RT-PCR (adiponectin, MCP-1, TNF-α, CD68, matrix metalloprotease (MMP)-2, MMP-9). Macrophage infiltration in aortic wall and retroperitoneal periaortic fat among group P was significantly decreased compared to that among group C. Adiponectin expressions in both subcutaneous fat and retroperitoneal periaortic fat among the group P (adiponectin/β-actin) were significantly increased compared to those among the group C [subcutaneous fat; 16.8 ± 13.9 vs. 5.82 ± 2.94 (P = 0.04), retroperitoneal periaortic fat; 21.3 ± 24.1 vs. 2.12 ± 1.69 (P = 0.04)]. On the other hand, expressions of TNF-α, and MMP-9 in both aortic aneurysmal wall and retroperitoneal periaortic fat among group P were significantly decreased. [(Aortic aneurysmal wall; TNF-α; 0.45 ± 0.15 vs. 5.18 ± 3.49 (P = 0.02), MMP-9; 39.6 ± 69.0 vs. 721 ± 741 (P = 0.04)], [retroperitoneal periaortic fat; TNF-α; 1.14 ± 0.36 vs. 26.4 ± 25.0 (P = 0.048), MMP-9; 0.18 ± 0.21 vs. 50.0 ± 41.8 (P = 0.047)]. These data may indicate that PPAR-γ agonist become the way for preventing or delaying aortic aneurysm progression in patients. More studies will be needed to clarify this drug effects in detail.
Tài liệu tham khảo
Kuwano H, Amano J, Yokomise H. Thoracic and cardiovascular surgery in Japan during 2010: annual report by The Japanese Association for Thoracic Surgery. General thoracic and cardiovascular surgery. 2012;60(10):680–708.
Tadros RO, et al. (2014) The impact of stent graft evolution on the results of endovascular abdominal aortic aneurysm repair. Journal of vascular surgery.
Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation. 2005;111(6):816–28.
Krishna SM, Dear AE, Norman PE, Golledge J. Genetic and epigenetic mechanisms and their possible role in abdominal aortic aneurysm. Atherosclerosis. 2010;212(1):16–29.
Tang PC, et al. Hyperplastic cellular remodeling of the media in ascending thoracic aortic aneurysms. Circulation. 2005;112(8):1098–105.
Eagleton MJ. Inflammation in abdominal aortic aneurysms: cellular infiltrate and cytokine profiles. Vascular. 2012;20(5):278–83.
Klink A, et al. Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. Nature reviews. Cardiology. 2011;8(6):338–47.
Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nature reviews. Cardiology. 2011;8(2):92–102.
Jagadesham VP, Scott DJ, Carding SR. Abdominal aortic aneurysms: an autoimmune disease? Trends in molecular medicine. 2008;14(12):522–9.
Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2008;153(4):636–45.
Wang N, Yin R, Liu Y, Mao G, Xi F. Role of peroxisome proliferator-activated receptor-gamma in atherosclerosis: an update. Circulation journal : official journal of the Japanese Circulation Society. 2011;75(3):528–35.
Zinn A, Felson S, Fisher E, Schwartzbard A. Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol. 2008;31(9):397–403.
Carpenter SW, et al. Acute aortic syndromes: definition, prognosis and treatment options. The Journal of cardiovascular surgery. 2014;55(2 Suppl 1):133–44.
Collins CG, Leahy AL. Screening of abdominal aortic aneurysms. The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 2006;4(2):83–5.
Ferket BS, et al. Systematic review of guidelines on abdominal aortic aneurysm screening. J Vasc Surg. 2012;55(5):1296–304.
Evangelista A. Imaging aortic aneurysmal disease. Heart. 2014;100(12):909–15.
Geisbusch S, et al. A prospective study of growth and rupture risk of small-to-moderate size ascending aortic aneurysms. The Journal of thoracic and cardiovascular surgery. 2014;147(1):68–74.
Miyake T, Morishita R. Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res. 2009;83(3):436–43.
Kurobe H, et al. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects. The Journal of thoracic and cardiovascular surgery. 2013;146(6):1501–8.
Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26(12):2605–13.
Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovascular diabetology. 2012;11:140.
Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B. The role of PPARs in atherosclerosis. Trends in molecular medicine. 2002;8(9):422–30.
Charo IF. Macrophage polarization and insulin resistance: PPARgamma in control. Cell Metab. 2007;6(2):96–8.
Liu YC, Zou XB, Chai YF, Yao YM. Macrophage polarization in inflammatory diseases. International journal of biological sciences. 2014;10(5):520–9.
Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Investig. 2012;122(3):787–95.
Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D. PPAR- gamma agonist in treatment of diabetes: cardiovascular safety considerations. Cardiovascular & hematological agents in medicinal chemistry. 2012;10(2):124–34.
Tseng CH & Tseng FH (2012) Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews 30(4):368-402.
Plissonnier ML, Fauconnet S, Bittard H, Lascombe I. The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL. PLoS ONE. 2011;6(12):e28354.